Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

levels of HCV RNA (<15 IU/mL), or RVR. Following 4 weeks of treatment with R7128 500mg BID with Pegasys plus Copegus, patients achieved a mean 3.82 log10 IU/mL decrease in HCV RNA and 30% (6 of 20) had RVR. Following 4 weeks of treatment with placebo with Pegasys plus Copegus, patients achieved a mean 2.95 log10 IU/mL decrease in HCV RNA and 10% (1 of 10) had RVR. The baseline HCV RNA levels for all patients in the study were greater than 6.3 log10 IU/mL and were similar across all study groups.

Safety Summary

Safety and tolerability for the 4-week treatment period were similar for R7128 with Pegasys plus Copegus compared to placebo with Pegasys plus Copegus. There were no serious adverse events reported during the 4-week treatment period, and most of the adverse events reported were of mild to moderate intensity. The most common adverse events, reported in 15% or greater of patients in any treatment group during the 4-week treatment period, were headache, injection site reaction, myalgia, fatigue, chills, rash, nausea, diarrhea, arthralgia, pyrexia, dizziness, dyspepsia and pruritis. The frequency and severity of these adverse events, as well as any general body system observations, were generally similar to clinical experience with the standard of care for HCV, pegylated interferon plus ribavirin.

Grade 3/4 neutropenia was observed in 30% of the placebo patients and in 10% to 15% of the R7128 patients in each active dosing cohort. Grade 3 changes in hemoglobin were observed in 10% of the placebo patients and in 15% of the R7128 patients. There were no clinically significant changes in other hepatic, renal, or other safety laboratory parameters, vital signs, or electrocardiograms.

Overall, there was no clinical evidence of any major organ toxicities related to R7128. One patient in the active treatment group discontinued the study during the 4 week treatment period due to lower-gastrointestinal adverse events. At the time of study discon
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...
(Date:12/15/2009)... Dec. 15 Dynatronics Corporation ... a preferred vendor agreement to provide therapy equipment ... (PTP), a nationwide network of physical, occupational and ... working with Preferred Therapy Providers," said Larry K. ... at Dynatronics. "Their vast network of 1,100 clinics ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... of the competitive environment is unquestionably ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 1Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 2Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 3Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 4Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 5Dallas Physician Elected to Lead International Organ Transplant Society 55053 1Dallas Physician Elected to Lead International Organ Transplant Society 55053 2Dallas Physician Elected to Lead International Organ Transplant Society 55053 3Gene Linked to Inherited Kidney Disease Found 55049 1
... PARIS, June 30 Five years after the ... disease causing accelerated and,premature ageing, a team of ... University of Oviedo - and Nicolas Levy and ... treatment,for the disease, using mice. This treatment, combining ...
... LONDON and PHILADELPHIA, June 30 ,GlaxoSmithKline (NYSE: GSK ... the U.S. Food and Drug Administration (FDA) for approval,of ... has submitted its response to questions raised by the ... In addition, given,that final data from GSK,s Phase III ...
Other Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 2GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 3
(Date:12/15/2009)... WHITE PLAINS, N.Y., Dec. 15 Team ... (LLS) groundbreaking charity sports training program, ... billion to support blood cancer research and patient ... has been the pre-eminent charity endurance sports training ... a marathon, half marathon, triathlon, 100-mile century cycle ...
(Date:12/15/2009)... 15 The new compact LifeSpan TR200 folding ... www.LifeSpanFitness.com ), was highly praised by treadmill review ... 2010. The compact TR200 folding treadmill received awards for ... under $1000. ,, The compact LifeSpan TR200 treadmill ... workout spaces. "This category buster is a very compact ...
(Date:12/15/2009)... to reduce depression and fatigue in people struggling with ... stems from an individual,s sense of mastery over ... certain physical goals. , The study appears in ... our arguments on fatigue being a symptom of depression," ... health at the University of Illinois and lead author ...
(Date:12/15/2009)... decade, the United Nations Foundation has led the fight ... World Malaria Report 2009 that the global strategies for ending malaria ... Health for the United Nations Foundation , ... Washington, ... United Nations Foundation has led the fight against malaria, ...
(Date:12/15/2009)... that phthalates actually cause the condition, experts ... Common chemicals found in plastic toys and elsewhere ... in boys, preliminary research suggests. , The ... pediatricians, adds fuel to the debate over these ... by some scientists. The chemical industry claims the ...
Breaking Medicine News(10 mins):Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3
... to provide additional modality integrationsINDIANAPOLIS, March 9 ... pleased to announce the worldwide release of its ... Key features of this release include integrated ECG ... Hemodynamic system. Synapse ProSolv cardiovascular 4.0.1 will ...
... Improvement Plus to Provide Information on Medicare Advantage ... Farmers MarketCOLUMBIA, S.C., March 9 A series ... Medicare beneficiaries with chronic illness maintain a healthy ... Plans designed for their unique needs will be ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... the latest findings in laboratory, translational and clinical cancer ... therapeutic approaches, as well as strides being made in ... the best advantage of the meeting,s scientific abstracts and ... will be available online at www.aacr.org on Friday, March ...
... Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., March ... IDMI ) today announced that the European Commission ... (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, ... that typically affects children and young adults. The ...
... author reviews the consequencesROCHESTER, Minn., March 9 ... the treating physician recommends discharge, the consequences may ... the need for readmission, according to a review ... Proceedings. Additionally, the article examines the effect of ...
Other Medicine News:Health News:ProSolv Releases New Cardiovascular Software 2Health News:ProSolv Releases New Cardiovascular Software 3Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3
... improved OrthoWedge® Healing Shoe offers the most ... forefoot while allowing patients to maintain their ... wedge, an even larger portion of the ... the metatarsal heads and toes to heal ...
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... is a given with our High Beam TriLens ... and remarkably brilliant 11.5 cm spot at a ... its class. , ,To achieve this unequaled performance ... with three of the finest Mag-Fluoride coated lenses ...
Medicine Products: